Skip to content. Skip to main navigation.

Tethys Bioscience

Pinpointing risk to help prevent disease.

A key to forestalling the development of preventable cardiometabolic diseases such as type 2 diabetes is being able to identify those individuals at greatest risk, so that scarce healthcare resources can be targeted toward the patients who will benefit most from early and aggressive intervention.

Learn More

The PreDx platform for preemption.

Tethys creates and commercializes novel blood tests that utilize a highly accurate, multi-marker measurement technology to assess time-based disease risk.

Learn More

The PreDx® Platform redefines disease prevention.

More accurate risk assessment empowers physicians to make better-informed patient management decisions that can delay and even prevent the onset of chronic conditions.

Learn More
PreDx

News

  1. 12/7/2011 Tethys and ACAP Help Employers Prevent Diabetes
  2. 10/12/2011 Tethys is Granted New York State Laboratory Permit for PreDx® Diabetes Risk Score
  3. 9/1/2011 Tethys Selected as 2012 Technology Pioneer by the World Economic Forum for Innovation in Diagnostics
  4. 8/1/2011 Tethys PreDx® DRS Shows Superior Accuracy in Assessing Type 2 Diabetes Risk vs. Metabolic Syndrome

View past news entries »

Events

View all Tethys events »